Letonya - Letonca - Zāļu valsts aģentūra

fresenius kabi ab, sweden - alaninum, argininum, glycinum, histidinum, isoleucinum, leucinum, lysinum, methioninum, phenylalaninum, prolinum, serinum, liellopu gaļas, threoninum, tryptophanum, tyrosinum, valinum, kalcija chloridum, natrii glycerophosphas, magnija sulfas, kalii chloridum, natrii acetas, un zinci sulfas, glikozi, soiae naftas raffinatum, triglycerida saturata mediju, olīveļļa raffinatum, zivju eļļa omega-3 taukskābēm bagāti - emulsija infūzijām

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

dion sportlab, sia - tablete

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

dion sportlab, sia - tablete

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

dion sportlab, sia - tablete

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

dion sportlab, sia - kapsula

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

skin nutrition international inc. - kapsula

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - cūkas - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glikogēna uzglabāšanas slimības ii tipa - citas gremošanas trakta un metabolisma produkti, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glikogēna uzglabāšanas slimības ii tipa - citas gremošanas trakta un metabolisma produkti, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabriku slimība - citas gremošanas trakta un metabolisma produkti, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).